Which medications in the drug class Alpha 4 Integrin Inhibitors are used in the treatment of Crohn Disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

Alpha 4 Integrin Inhibitors

Integrin inhibitors are emerging as options for moderate-to-severe active IBD in patients who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.

Natalizumab (Tysabri)

Natalizumab is indicated for moderate-to-severe Crohn disease in patients who have had inadequate responses to other therapies. It is a monoclonal antibody that binds α4β7 and α4β1 that results in inhibition of leukocyte adhesion and migration to areas of inflammation.

Vedolizumab (Entyvio)

Vedolizumab is a recombinant humanized monoclonal antibody that binds specifically to α4β7 integrin. It blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. It is indicated for both ulcerative colitis and Crohn disease.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!